NCT03464448View on ClinicalTrials.gov

Mechanistic Studies of Teriflunomide in RRMS

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

October 13, 2021

Study Completion Date

October 13, 2021

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Teriflunomide

AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT03464448 - Mechanistic Studies of Teriflunomide in RRMS | Biotech Hunter | Biotech Hunter